Anavex Life Sciences CORP

Anavex Life Sciences Corp. has appointed Terrie Kellmeyer, Ph.D., as its permanent President and Chief Executive Officer, effective November 1, 2026.

Anavex Life Sciences Corp. announced the resignations of three board members, citing strategic disagreements with management.

Anavex Life Sciences announced the completion of clinical conduct for two key pharmacology studies of blarcamesine (ANAVEX2-73), advancing its development programs for Alzheimer's, Rett, and Fragile X syndromes.

Anavex Life Sciences announced it has received FDA clearance to proceed with a clinical study for blarcamesine in Fragile X syndrome, opening INDs for all three core indications.

Anavex Life Sciences Corp. held its 2026 Annual Meeting of Stockholders, confirming director elections and auditor ratification, while also triggering a change in control event.

Anavex Life Sciences Corp. announced an upcoming FDA meeting to discuss the inclusion of pediatric patients in its Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome.

Anavex Life Sciences reported a reduced net loss in Q1 2026, bolstered by a $36.3 million equity raise, while its Alzheimer's drug, blarcamesine, faces an EMA re-examination after a negative trend-vote.

Anavex Life Sciences Corp. reported an increased net loss for Q3 2025, alongside significant progress in its Alzheimer's and schizophrenia clinical programs and new capital raising initiatives.

Anavex Life Sciences Corp. files its 10-Q report for the quarter ended March 31, 2025, detailing financial results and providing updates on its clinical development programs.

Anavex Life Sciences Corp. reports a net loss for Q1 2025, alongside updates on its clinical trials for ANAVEX2-73 and ANAVEX3-71.

Anavex Life Sciences Corp. released its Q3 2024 financial results, detailing ongoing clinical trials and financial status.

Anavex Life Sciences Corp. released its financial results for the second quarter of 2024, alongside updates on its clinical development programs.

Anavex Life Sciences Corp. files an amendment to its annual report, disclosing a material weakness in internal controls and restating its financial reporting opinion.

Anavex Life Sciences reports a negative trend vote from the EMA for its Alzheimer's drug blarcamesine, alongside increased net losses and decreased cash reserves for fiscal year 2025.

Anavex Life Sciences Corp. files its annual report, highlighting clinical trial progress, regulatory submissions, and financial results for the fiscal year ended September 30, 2024.

Claus Vander Velden, a Director of Anavex Life Sciences Corp., received 50,000 shares of common stock on November 3, 2026.

Peter D.O. Donhauser, a Director of Anavex Life Sciences Corp., received 50,000 shares of common stock on November 3, 2026.

Terrie Kellmeyer, President and CEO and a Director of Anavex Life Sciences Corp., received 200,000 shares of common stock on November 3, 2026.

Axel Paeger, a Director of Anavex Life Sciences Corp., received 50,000 shares of common stock on November 3, 2026.

Sandra Boenisch, PFO & Treasurer of Anavex Life Sciences Corp., reported multiple transactions in common stock on September 24, 2026.

ANAVEX LIFE SCIENCES CEO Christopher U. Missling's stock options for 125,000 shares vested following the achievement of a key performance milestone related to blarcamesine's regulatory dialogue.

Anavex Life Sciences Corp. has filed a definitive proxy statement with the SEC.

Anavex Life Sciences is asking stockholders to approve an amendment to its 2022 Omnibus Incentive Plan, including increasing the number of shares available and establishing a minimum vesting period.

ANAVEX Life Sciences Corp. has filed a definitive proxy statement with the SEC.

Anavex Life Sciences Corp. has released its proxy statement outlining the agenda and procedures for its 2024 Annual Meeting of Stockholders, scheduled for June 18, 2024.

Vanguard Capital Management has reported beneficial ownership of 5.03% of Anavex Life Sciences Corp. common stock as of June 30, 2026.

The Vanguard Group filed an amendment to its Schedule 13G for Anavex Life Sciences Corp., reporting zero beneficial ownership following an internal realignment.